Patents by Inventor Jake Shortt

Jake Shortt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL KINASE-BROMODOMAIN INHIBITORS
    Publication number: 20230312577
    Abstract: Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 5, 2023
    Inventors: Philip THOMPSON, Jake SHORTT, Ricky JOHNSTONE, Xiao MA, Danielle OH, Ian JENNINGS
  • COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE
    Publication number: 20190192532
    Abstract: The present disclosure provides combination therapy of a bromodomain inhibitor and an immune modulator (e.g., an immune check point inhibitor). The combination of the bromodomain inhibitor and the immune modulator may be useful in treating or preventing cancer in a subject. In certain embodiments, the subject has an intact immune system. The combination of the bromodomain inhibitor and the immune modulator is expected to be synergistic.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 27, 2019
    Inventors: James E. Bradner, Simon John Hogg, Ricky Wayne Johnstone, Jake Shortt
  • Stimulating immune response
    Patent number: 9724329
    Abstract: Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: August 8, 2017
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Andy Kang-Wei Hsu, Jake Shortt, Paul Neeson, Ricky Wayne Johnstone, David Ritchie
  • STIMULATING IMMUNE RESPONSE
    Publication number: 20130302377
    Abstract: Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent.
    Type: Application
    Filed: June 21, 2011
    Publication date: November 14, 2013
    Applicant: PETER MACCALLUM CANCER INSTITUTE
    Inventors: Andy Kang-Wei Hsu, Jake Shortt, Paul Neeson, Ricky Wayne Johnstone, David Ritchie